Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions (NYSE: EBS) announced a conference call scheduled for May 9, 2023, at 5:00 PM ET to discuss its first-quarter financial results, recent business developments, and revenue guidance for Q2 2023 and the full year.
Participants can join the call via webcast on Emergent's Investors page or register for telephone access to receive a confirmation email with dial-in details. A replay will be available on the same page.
Emergent focuses on protecting public health through vaccines and therapeutics, providing contract services to pharmaceutical firms. The company aims to enhance one billion lives by 2030.
Emergent BioSolutions (NYSE: EBS) has received FDA approval for NARCAN® Naloxone HCl Nasal Spray 4 mg, making it the first over-the-counter (OTC) naloxone spray in the U.S. This pivotal approval aims to combat the escalating opioid crisis, where someone dies from an overdose every eight minutes. NARCAN will be available without a prescription by late summer 2023. Since its launch in 2016, over 44 million doses have been distributed. The product retains its original formulation and strength, essential for reversing opioid effects. Emergent is committed to enhancing public health and facilitating access to life-saving treatments.
Emergent BioSolutions reported Q4 2022 revenues of $331 million, totaling $1.121 billion for FY 2022, in line with guidance. The company faced a net loss of $88 million for Q4 and $224 million for the full year. Adjusted EBITDA for Q4 was $34 million, with an adjusted gross margin of 48%. Looking ahead, Emergent projects FY 2023 revenues between $1.1 billion and $1.2 billion, with adjusted EBITDA expected to reach $100 million. The company anticipates improved operations and cost structures as it focuses on patient and customer priorities.
Emergent BioSolutions (NYSE:EBS) received a unanimous recommendation from the FDA’s advisory committees for the over-the-counter sale of NARCAN Nasal Spray, a 4 mg naloxone product for opioid overdose reversal. This vote supports expanding access to NARCAN, crucial amid rising overdose deaths, particularly those linked to synthetic opioids like fentanyl. In 2021, over 70,000 American lives were lost to such overdoses. The FDA's decision, expected by March 29, 2023, marks a significant step in addressing this public health crisis. Emergent aims to collaborate with stakeholders to enhance access and awareness of NARCAN as a lifesaving treatment.
Emergent BioSolutions (NYSE: EBS) has signed an agreement to sell its travel health business to Bavarian Nordic for up to $380 million, including future milestones. This includes the rights to VIVOTIF® and VAXCHORA® vaccines and a chikungunya vaccine candidate. Emergent will receive $270 million upfront, with potential additional payments of $110 million based on sales and development milestones. The transaction aims to enhance Emergent's focus on its core medical countermeasure products, improving profitability and fostering sustainable growth. The deal is expected to close in Q2 2023, pending regulatory approvals.
Emergent BioSolutions (NYSE: EBS) will conduct a conference call on February 27, 2023 at 5:00 PM ET to discuss its Q4 2022 financial results, recent business developments, and the 2023 financial outlook. Participants can join via webcast or telephone after registering in advance. The replay will be available on the company’s Investors page.
Emergent BioSolutions (NYSE: EBS) announced preliminary financial results for 2022, projecting total revenues between $1,100 million and $1,120 million, reflecting a 38% decrease from 2021. The company anticipates a net loss of $210 million to $190 million and an Adjusted EBITDA of $20 million to $40 million, down 94% year-over-year. Key strategic changes include the appointment of new leadership and a workforce reduction of 132 roles to achieve over $60 million in annual savings. Emergent plans to refocus on its core medical countermeasures and commercial products, with financial outlook for 2023 forthcoming.
Emergent BioSolutions (NYSE:EBS) has secured an indefinite-delivery, indefinite-quantity contract valued at up to $379.6 million to supply the Reactive Skin Decontamination Lotion Kit (RSDL®) to the U.S. military. The contract includes a base year starting December 2022 and four optional annual renewals. RSDL® has been utilized by the U.S. for 13 years and is designed to neutralize chemical warfare agents. Emergent emphasizes its commitment to public health and military preparedness through this contract.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
